Related Experiment Videos
Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
D S Schrump1, W Matthews, G A Chen
1Thoracic Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892-1502, USA.
Abstract:
Esophageal adenocarcinoma (SKGT-2, SKGT-4, and SKGT-5) and epidermoid carcinoma (HCE-4) cells containing variable retinoblastoma (Rb), cyclin D1, p16, and p53 expression patterns were exposed to the synthetic flavone, flavopiridol. The IC50 was approximately 100-150 nM for each of these cell lines. Exposure of esophageal carcinoma cells to 300 nM flavopiridol induced cell cycle arrest and apoptosis, resulting in a 90% inhibition of proliferation relative to that of nontreated cells after a 5-day exposure to the drug. Western blot analysis revealed diminution of cyclin D1, Rb, and p107 protein levels after flavopiridol exposure. Whereas cell cycle arrest and overall growth inhibition did not correlate in any obvious manner with the genotype of these cell lines, apoptosis seemed to be more pronounced in SKGT-2 and SKGT-4 cells that lack Rb expression. Pretreatment of esophageal cancer cells with 9-cis-retinoic acid did not substantially potentiate flavopiridol activity in these cell lines. Although the precise mechanism of flavopiridol-mediated cytotoxicity has not been fully defined, this drug is an attractive agent for molecular intervention in esophageal cancers and their precursor lesions; further evaluation of flavopiridol in this clinical context is warranted.
Insights
Flavopiridol effectively inhibits esophageal cancer cell proliferation by inducing cell cycle arrest and apoptosis. This synthetic flavone demonstrates potential as a targeted therapy for esophageal cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Esophageal cancer encompasses adenocarcinoma and epidermoid carcinoma.
- Cell cycle regulators like retinoblastoma (Rb), cyclin D1, p16, and p53 play crucial roles in cancer development.
- Understanding the impact of targeted therapies on these pathways is vital.
Purpose of the Study:
- To investigate the efficacy of the synthetic flavone flavopiridol against esophageal cancer cell lines.
- To determine the effects of flavopiridol on cell cycle progression, apoptosis, and protein expression.
- To explore potential correlations between cellular genotype and drug response.
Main Methods:
- Exposure of esophageal cancer cell lines (SKGT-2, SKGT-4, SKGT-5, HCE-4) to varying concentrations of flavopiridol.
- Determination of IC50 values.
- Assessment of cell proliferation, cell cycle arrest, and apoptosis via cell-based assays.
- Western blot analysis to evaluate protein levels (cyclin D1, Rb, p107).
Main Results:
- Flavopiridol exhibited an IC50 of approximately 100-150 nM across tested cell lines.
- A concentration of 300 nM flavopiridol induced significant cell cycle arrest and apoptosis, inhibiting proliferation by 90% after 5 days.
- Western blot analysis showed decreased levels of cyclin D1, Rb, and p107 proteins.
- Apoptosis was more pronounced in Rb-deficient cell lines (SKGT-2, SKGT-4).
Conclusions:
- Flavopiridol demonstrates potent anti-proliferative and cytotoxic effects on esophageal cancer cells.
- The drug induces cell cycle arrest and apoptosis, with potential differential effects based on Rb expression.
- Flavopiridol is a promising candidate for molecular intervention in esophageal cancers and precursor lesions, warranting further clinical investigation.